Phyo, Aung Zaw Zaw http://orcid.org/0000-0002-8834-4072
Fransquet, Peter D.
Wrigglesworth, Jo
Woods, Robyn L.
Espinoza, Sara E.
Ryan, Joanne
Funding for this research was provided by:
National Institute on Aging and the National Cancer Institute at the U.S. National Institutes of Health (U01AG029824, U19AG062682)
National Health and Medical Research Council of Australia (334047, 1127060, 1086188)
Monash University (Australia) and the Victorian Cancer Agency (http://www.aspree.org)
Other funding resources and collaborating organizations of the ASPREE study (http://www.aspree.org)
National Health and Medical Research Council Leadership 1 Investigator Grant (2016438)
Monash University
Article History
Received: 31 July 2023
Accepted: 11 September 2023
First Online: 25 September 2023
Declarations
:
: The data of the present secondary data-analysis study was from a five-year ASPREE clinical trial (Trial Registration: International Standard Randomized Controlled Trial Number Register (ISRCTN 83772183) and clinicaltrials.gov (NCT 01038583)). The ASPREE trial was approved by multiple Institutional Review Boards in Australia and the USA (ExternalRef removed). The current study was approved by the Monash University Human Research Ethics Committee (MHREC 30734).
: All authors gave their approval for submission.
: All individual participants of the ASPREE study including the ASPREE Biobank and ASPREE-NEURO sub-studies signed informed consent on participation.
: No animals were used for this research. The study on humans was conducted in accordance with the Declaration of Helsinki 2008 revision, NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law, the International Conference of Harmonisation Guidelines for Good Clinical Practice, and the Code of Federal Regulations. ASPREE also follows the Code of Federal Regulations as it relates to areas of clinical research. The overall management and conduct of the ASPREE clinical trial are the responsibility of the ASPREE Steering Committee.
: The authors declare no competing interests.